Maricann Group (CNSX:MARI – Get Free Report) had its price target raised by investment analysts at National Bankshares from $7.50 to $11.00 in a report released on Friday,BayStreet.CA reports. The brokerage currently has an “outperform” rating on the stock.
Separately, BMO Capital Markets raised their target price on shares of Maricann Group from $7.00 to $9.50 and gave the stock an “outperform” rating in a research note on Friday.
Get Our Latest Stock Report on Maricann Group
Maricann Group Price Performance
About Maricann Group
Maricann Group Inc, formerly Danbel Industries Corporation, is a Canada-based integrated producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal license to cultivate cannabis and one of approximately 30 independent licensed producers with a federal license to process and distribute cannabis, the Company’s services a patient base with more than 8,000 registered patients.
Read More
- Five stocks we like better than Maricann Group
- A Deeper Look at Bid-Ask Spreads
- 3 Defense Leaders Set to Gain From Rising Military Spend
- Growth Stocks: What They Are, Examples and How to Invest
- Why the Schwab Dividend ETF Rallied—and Can It Keep Climbing?
- Best Aerospace Stocks Investing
- MarketBeat Week in Review – 06/30 – 07/04
Receive News & Ratings for Maricann Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maricann Group and related companies with MarketBeat.com's FREE daily email newsletter.
